Yes you’re right.,I’d picked up on that too, looks like the BIS committee were strict with approving how device could be used (concerning the associated chemo) and didn’t allow it to be used with “folfirinox” chemo , —guess they must have thought not enough patients given that combination in Pancor trial to prove it was ok. in fact the ceo was asked about this at an investor call he said there was some pushback in Europe from oncologists not being able to use device with folfinox but he didn’t think it was a problem. Perhaps they’ve underestimated this issue .not sure maybe an ok use for device could be in weaker patients who can’t hack stronger modern chemo and have to stick with gemcitabine? Is that a strategy for company to at least get it funded, used as bit of a reserve therapy, limit it. better than nothing at least gets some sales curious to know how Sirtex managed this in Europe when they started selling, did they get funded anywhere early.
OSL Price at posting:
16.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)